IP Verse

Solid Preparation - EP3263110

The patent EP3263110 was granted to Takeda Pharmaceutical on May 10, 2023. The application was originally filed on Feb 25, 2016 under application number EP16755593A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3263110

TAKEDA PHARMACEUTICAL
Application Number
EP16755593A
Filing Date
Feb 25, 2016
Status
Granted And Under Opposition
Apr 7, 2023
Grant Date
May 10, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZFeb 8, 2024ELKINGTON AND FIFEADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONEP2329823
INTERNATIONAL-SEARCH-REPORTJP2001278884
INTERNATIONAL-SEARCH-REPORTJP2003292492
INTERNATIONAL-SEARCH-REPORTJP2004250439
INTERNATIONAL-SEARCH-REPORTJPH08295693
INTERNATIONAL-SEARCH-REPORTWO2004067535
INTERNATIONAL-SEARCH-REPORTWO2010026993
OPPOSITIONEP2329823
OPPOSITIONUS2006160829
OPPOSITIONUS2014199236
SEARCHEP2329823
SEARCHUS2014199236

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Allen Jr L V, Luner, P E, "Magnesium Stearate", Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (20090203), pages 404 - 407, XP055956908-
OPPOSITION- Anonymous, "Hydroxypropyl Cellulose", Anonymous, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 317 - 321, ISBN 978-0-85369-792-3, XP093163295-
OPPOSITION- Anonymous, "PEARLITOL 100 SD Mannitol", Innovation Hub Pharma Virtual Lab by roquette - Product Profile, Roquette Frères, (20240516), pages 1 - 4, Innovation Hub Pharma Virtual Lab by roquette - Product Profile, URL: https://www.roquette.com/innovation-hub/pharma/product-profile-pages/pearlitol-100sd-mannitol, XP093163313-
OPPOSITION- Anonymous, "PEARLITOL® 200 SD Mannitol", Innovation Hub Pharma Virtual Lab by roquette - Product Profile, Roquette Frères, (20240516), pages 1 - 4, Innovation Hub Pharma Virtual Lab by roquette - Product Profile, URL: https://www.roquette.com/innovation-hub/pharma/product-profile-pages/pearlitol-200sd-mannitol, XP093163342-
OPPOSITION- Anonymous, "PRODUCT SPECIFICATION SHEET PEARLITOL® 100 SD", PRODUCT SPECIFICATION SHEET, Roquette Frères, (20231031), pages 1 - 3, PRODUCT SPECIFICATION SHEET , URL: https://www.roquette.com/-/media/roquette-sharepoint-libraries/product-specification-sheet/2023/11/03/00/20/roquette_pspe_y048_pearlitol-100-sd_000000200344_en.pdf, XP093163319-
OPPOSITION- Anonymous, "Section 2.9.31 - Particle Size Analysis by Laser Light Diffraction", European Pharmacopoeia 6.0, (20070723), pages 311 - 314, XP055638472-
OPPOSITION- Anonymous, "What is/are the difference(s) between PEARLITOL ® C, SD and DC Mannitol grades? ", Troubleshooting and FAQs for PEARLITOL® Mannitol, Roquette Frères, (20240516), pages 1 - 4, Troubleshooting and FAQs for PEARLITOL® Mannitol, URL: https://www.roquette.com/innovation-hub/pharma/troubleshooting-and-faq/pearlitol-mannitol/what-isare-the-differences-between-pearlitol-c-60a055f8-6ec2-4f1d-9f6e-0936e62df5a5, XP093163328-
OPPOSITION- Anonymous, "What is the crystal form of PEARLITOL ® C?", Troubleshooting and FAQs for PEARLITOL® Mannitol, Roquette Frères, (20240516), pages 1 - 4, Troubleshooting and FAQs for PEARLITOL® Mannitol, URL: https://www.roquette.com/innovation-hub/pharma/troubleshooting-and-faq/pearlitol-mannitol/what-is-the-crystal-form-of-pearlitolreg-47ab6c3e-4b9e-4f0b-87e3-44904cd347ae, XP093163334-
OPPOSITION- Anonymous, "What is the crystal form of PEARLITOL ® SD Mannitol?", Troubleshooting and FAQs for PEARLITOL® Mannitol, Roquette Frères, (20240516), pages 1 - 4, Troubleshooting and FAQs for PEARLITOL® Mannitol, URL: https://www.roquette.com/innovation-hub/pharma/troubleshooting-and-faq/pearlitol-mannitol/what-is-the-crystal-form-of-pearlitol-e1d466ea-3fab-4cb7-b073-7452a47fd957, XP093163338-
OPPOSITION- "ISO 13320-1:1999 Particle size analysis - Laser diffraction methods. Part 1: General Principles", INTERNATIONAL STANDARD - ISO, ZUERICH, CH, CH , (19991101), vol. 13320-1, pages 41 pp. - 1st ed., XP009127188-
OPPOSITION- Millennium Pharmaceuticals, Inc., "NCT02135445 Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer", ClinicalTrials.gov, NLM, (20150106), pages 1 - 15, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02135445?cond=NCT02135445&rank=1&tab=history&a=2, XP093163324-
OPPOSITION- N.A.Armstrong, "Mannitol", N.A.Armstrong, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 424 - 428, ISBN 978-0-85369-792-3, XP055694353-
OPPOSITION- Raymond C. Rowe, "Sodium Starch Glycolate", Raymond C. Rowe, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 663 - 666, ISBN 978-0-85369-792-3, XP093163307-
OPPOSITION- Sakr Ahmed Adel, Et Al, "Chapter 30 oral solid dosage forms", Remington Essentials of Pharmaceutics, Pharmaceutical Press , (20120101), pages 581 - 610, XP055795831-
OPPOSITION- Stuart C. Porter, "Chapter 31 Coating of Pharmaceutical Dosage Forms", Remington, Essentials of Pharmaceutics, GB, Pharmaceutical Press , (20130101), pages 611 - 621, ISBN 978-0-85711-105-0, XP093163236-
OPPOSITION- Us Pharmacopoeia, "Chapter 429: Light Diffraction Measurement of Particle Size", (20150501), pages 294 - 299, XP055821992-
OPPOSITION- William J. Reilly, "Chapter 36 Pharmaceutical Excipients", Remington, Essentials of Pharmaceutics, GB, Pharmaceutical Press , (20130101), pages 683 - 704, ISBN 978-0-85711-105-0, XP093163239-
OPPOSITION- Kazuhiro Miwa, Takenori Hitaka, Takashi Imada, Satoshi Sasaki, Mie Yoshimatsu, Masami Kusaka, Akira Tanaka, Daisuke Nakata, Shuichi Furuya, Satoshi Endo, Kazumasa Hamamura, Tomoyuki Kitazaki, "Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3- d ]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor", Journal of Medicinal Chemistry, American Chemical Society, (20110728), vol. 54, no. 14, doi:10.1021/jm200216q, ISSN 00222623, pages 4998 - 5012, XP055012890
OPPOSITION- Rakesh Pahwa, "SUPERDISINTEGRANTS IN THE DEVELOPMENT OF ORALLY DISINTEGRATING TABLETS: A REVIEW", International Journal of Pharmaceutical Sciences and Research, Society of Pharmaceutical Sciences and Research, IN, IN , (20111101), vol. 2, no. 11, doi:10.13040/IJPSR.0975-8232.2(11).2767-80, ISSN 0975-8232, pages 2762 - 2780, XP093163225
OPPOSITION- Ohrem H. Leonhard, Schornick Eva, Kalivoda Adela, Ognibene Roberto, "Why is mannitol becoming more and more popular as a pharmaceutical excipient in solid dosage forms?", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, US , (20140526), vol. 19, no. 3, doi:10.3109/10837450.2013.775154, ISSN 1083-7450, pages 257 - 262, XP093105531

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents